The DESTINY-Gastric02 study is a very important study because it’s the first study in western patients with HER2 positive Gastric or Gastroesophageal junction adenomas who were progressive on trastuzumab containing chemotherapy. And then, the patients were treated with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhurtu). This was a study Western in patients and it’s following the … Continue reading Enhurtu (fam-trastuzumab deruxtecan-nxki) HER2 in Gastroesophageal Cancer